Rosiglitazone

\nIn medicine and pharmacology, rosiglitazone is a member of the drug class of the thiazolidinediones. It is being marketed as Avandia® by the pharmaceutical company GlaxoSmithKline, both as a standalone preparation and in combination with metformin (Avandamet®). Like other thiazolidinediones, its mechanism of action is by activation the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a pure ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone (Mohanty et al).

Table of contents

1 References 2 Side-effects and contraindications 3 See also 4 External links

References

\n* Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, al-Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect\nof rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.

Side-effects and contraindications

\nSee main article: thiazolidinedione

See also

\n* Anti-diabetic drugs\n* Peroxisome proliferator-activated receptor

External links

\n* Diabetes monitor article\n* MedlinePlus article\n*Avandia / Rosiglitazone Fact Sheet\nCategory:Anti-diabetic drugs